Results 81 to 90 of about 12,211 (152)

Serum biomarkers remain stable after transitioning from intravenous to subcutaneous natalizumab in multiple sclerosis. [PDF]

J Neurol
Muñoz-Vendrell A, Arroyo-Pereiro P, León I, Bau L, Matas E, Romero-Pinel L, Roca-Pereira S, Martínez-Yélamos A, Martínez-Yélamos S.   +8 more
europepmc   +1 more source

UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance. [PDF]

Mult Scler
Mullan G, Ford HL, Blackall P, Bongol D, Bonham N, Brex P, Hoyle N, Murray K, Nelson-Piercy C, Pearson OR, Rog D, Prinja P, Dobson R.   +12 more
europepmc   +1 more source

Effect of ocrelizumab on rates of retinal atrophy in relapsing multiple sclerosis. [PDF]

Mult Scler J Exp Transl Clin
McCormack B, Bacchetti A, Lin TY, Moretti GS, Filippatou A, Gakis G, O'Donnell MM, Lambert CM, Lee NJ, Ecoff K, Davis S, Otero-Duran G, Gulati A, Didouchevski A, Lievers E, Pellegrini N, Ezzedin O, Lambe J, Moussa H, Fitzgerald K, Newsome SD, Mowry EM, Sotirchos ES, Calabresi PA, Nourbakhsh B, Saidha S.   +25 more
europepmc   +1 more source

Digital signatures of fatigue and wearing-off symptoms in patients with multiple sclerosis under natalizumab. [PDF]

Neurotherapeutics
Masanneck L, Trautmann E, von Pavel J, Hagler R, Vach M, Kirschner P, Voth J, Schuette M, Benkert P, Kuhle J, Kaufmann J, Deffner M, Schwab N, Pfeuffer S, Meuth SG, Pawlitzki M.   +15 more
europepmc   +1 more source

Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.

Health Technol Assess
Manzano CL, Sadek A, Cooper C, Tomlinson E, Wang H, Rice C, Tallantyre E, Rao-Middleton A, Whiting P, Thom H.   +9 more
europepmc   +1 more source

Visual and Neuro-Ophthalmic Manifestations of John Cunningham (JC) Virus-Related Natalizumab-Associated Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Systematic Review. [PDF]

Cureus
Jangirashvili T, Parthiv O, Shengelia L, Tabeshadze Z, Kontchoshvili A, Waked CA, Tamer RM.   +6 more
europepmc   +1 more source

Inter-assay variability in anti-JC virus serology in the era of natalizumab biosimilars: implications for PML risk stratification. [PDF]

Front Immunol
Caminero AB, Oreja-Guevara C.
europepmc   +1 more source

"Home": How Immune Cells Enter the Central Nervous System. [PDF]

Neurol Neuroimmunol Neuroinflamm
Steinman L.
europepmc   +1 more source

Treatment persistence in paediatric-onset multiple sclerosis: A Swedish nationwide registry study. [PDF]

Mult Scler
Sandesjö F, McKay KA, Fink K, Piehl F, Wickström R.   +4 more
europepmc   +1 more source

Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis. [PDF]

Front Immunol
Buhelt S, Hansen MB, Søndergaard HB, El Mahdaoui S, Hansen MM, Mahler MR, Romme Christensen J, Sellebjerg F.   +7 more
europepmc   +1 more source